Core Insights - Defence Therapeutics Inc. is advancing its ADC and Radiopharma programs, focusing on collaborations and preclinical studies for cancer therapies using its Accum® technology [1][2][3] ADC Program - Defence's Accum®-based ADCs show improved intracellular delivery and cytotoxic activity in various preclinical cancer models compared to traditional ADCs [2] - The company is optimizing additional Accum®-based ADCs to enhance their value and attract potential licensing and co-development opportunities with Pharmaceuticals and Biotech companies [2] Radiopharmaceutical Program - The Radiopharma program is enhancing Accum® radiolabelling through studies conducted by Canadian Nuclear Laboratories, focusing on biodistribution, pharmacokinetics, and therapeutic potency [3] - The application of Accum® technology in the radiopharmaceuticals sector is expected to be transformative [3] Market Outlook - The global ADC market is projected to grow from USD 13.51 billion in 2025 to USD 29.9 billion by 2034, with a CAGR of 9.23% from 2024 to 2034 [4] - The global radiopharmaceutical market is expected to reach USD 16.87 billion by 2033, growing at a CAGR of 9.9% during 2025-2033 [4] Future Developments - The company plans to announce key results and partnership details as they become available, while continuing its studies in Canada and expanding its presence to the US [5] - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation ADC products using its proprietary Accum® technology [6]

Core Viewpoint - The article discusses the ongoing activities and offerings of a real estate investment community, emphasizing its growth and member satisfaction [1]. Group 1 - The community has over 2,000 members and maintains a perfect rating of 5/5 from more than 400 reviews [1]. - A limited-time offer is available for new members to join at a significantly reduced rate [1]. - The community provides a 2-week free trial for potential members to access the entire portfolio and current top picks [1].

Group 1 - iREIT+HOYA Capital focuses on income-producing asset classes that provide sustainable portfolio income, diversification, and inflation hedging [1] - Agree Realty (ADC) is recognized as a well-managed REIT with several positive attributes, making it a quality stock for accumulation during dips [2] - The article emphasizes a defensive investment approach with a medium- to long-term horizon [2] Group 2 - The article does not provide specific financial metrics or performance data related to Agree Realty or the broader REIT market [5]

Core Insights - Agree Realty (ADC) is recognized as the highest quality name in net lease REIT coverage due to its strategic capital allocation and careful underwriting practices [1] - The investment strategy emphasizes finding undervalued companies with strong balance sheets and management teams in sectors with long-term growth potential [1] Group 1 - The company has established its reputation through intentional efforts in capital allocation and underwriting [1] - The leader of the investing group Best Of Breed Growth Stocks focuses on stocks with a high probability of delivering significant alpha compared to the S&P 500 [1] - The investment approach combines growth-oriented principles with strict valuation hurdles to enhance the margin of safety [1] Group 2 - Features of the investment group include exclusive access to high-conviction stock picks, comprehensive research reports, real-time trade alerts, macro market analysis, and a community chat for continuous engagement [1] - The analyst's strategy involves identifying companies with secular growth that appreciate over time [1]

As an investor, I have been focused on buying and owning great businesses since day one. On the rare occasions that I strayed from this quality-first approach, IHi, my name is Kody. Aside from my articles here on Seeking Alpha, I am also a regular contributor to Sure Dividend, The Dividend Kings, and iREIT+Hoya Capital. I have been investing since September 2017 (age 20) and interested in dividend investing since about 2009.Since July 2018, I have ran Kody's Dividends. This is a blog that is documenting my ...

Group 1 - The S&P 500 reached new highs on June 30th due to progress in tariff trade deals [1] - The first half of the year experienced muted gains amid increasing uncertainty regarding global trade policy [1] Group 2 - The article emphasizes the importance of quality dividend-paying companies for building investment portfolios [1] - The author aims to assist lower and middle-class workers in achieving financial independence through dividend investing [1]

Group 1: Prologis Overview - Prologis is a leading industrial REIT with a market cap of nearly $100 billion, focusing on warehouses in key transportation hubs [2][4] - The company has demonstrated resilience amid tariff concerns, with a significant 32% increase in rents on renewing leases in Q1 2025 [5] - Prologis has maintained an average annualized dividend growth rate of 11% over the past decade, with a current yield of 3.8%, which is near the high end of its 10-year yield range [5] Group 2: Agree Realty Overview - Agree Realty is a smaller net lease REIT with a market cap of $8 billion, focusing on single-tenant retail properties across the U.S. [6][7] - The company has a diversified portfolio of over 2,400 properties and offers a current dividend yield of approximately 4.2% [7] - Agree Realty has achieved a dividend growth rate exceeding 5% over the past decade, outperforming larger competitors like Realty Income [8] Group 3: Investment Appeal - Both Prologis and Agree Realty provide a combination of attractive yield and dividend growth prospects, making them appealing options for dividend investors [9] - These REITs may not suit every dividend investor, but they offer a compelling mix of income and growth potential [9]

Group 1 - Akeso, Inc. has successfully enrolled the first patient in its Phase Ia clinical trial for AK146D1, a bispecific Antibody-Drug Conjugate (ADC) targeting Trop2 and Nectin4, marking its first bispecific ADC to enter clinical trials [1] - AK146D1 has received approvals from the U.S. FDA, Australia's TGA, and China's NMPA to begin clinical trials, indicating strong regulatory support for the product [1] - Akeso is the only company globally with two approved cancer immunotherapy bispecific antibodies, cadonilimab and ivonescimab, establishing a strong leadership advantage in the IO+ADC space [2] Group 2 - ADC therapeutics are a key component of Akeso's "IO+ADC" 2.0 strategy, which aims to reshape the global treatment landscape and set new standards for cancer care [3] - The company emphasizes the potential of innovative bispecific ADCs like AK146D1 to unlock global clinical opportunities and enhance cancer therapies [4] - Trop2 and Nectin4 are ideal targets for ADC therapy due to their high expression in various tumor types and low expression in normal tissues, which may improve treatment efficacy [4][5] Group 3 - AK146D1 is the first bispecific ADC targeting both Trop2 and Nectin4, with preclinical studies showing strong anti-tumor activity and favorable safety profiles [5] - The development of AK146D1 holds significant potential for improving treatment outcomes for cancer patients, highlighting Akeso's commitment to advancing cancer therapies [5]

Their share prices have crashed in the past three years, even as their cash flows and dividends kept rising, and as a result, valuations are today at a near 10-year low:Your timing is perfect! We’ve just released our latest top investment picks for July 2025, and by joining today, you’ll gain immediate access to these exciting opportunities.We invest thousands of hours and over $100,000 annually into researching the most profitable investment opportunities—all to bring you real estate strategies at just a f ...

LAUSANNE, Switzerland, July 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 17,000 of the Company's common shares to one new employee on July 1, 2025 (each, a "Grant").The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Boa ...